— Know what they know.
Not Investment Advice

DRRX NASDAQ

DURECT Corporation
1W: +0.0% 1M: +0.0% 3M: +218.3% 1Y: +30.8% 3Y: -71.1% 5Y: -88.8%
$1.91
Last traded 2025-09-11 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $59.3M mcap · 26M float · 4.51% daily turnover · Short 45% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$2M -76.2% ▼
5Y CAGR: -41.5%
Gross Profit
$2M -71.4% ▼
5Y CAGR: -40.1%
Operating Income
-$19M +48.7% ▲
Net Income
-$8M +69.9% ▲
EPS (Diluted)
$-0.27 +77.5% ▲
EBITDA
-$19M +23.7% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$30M$14M$19M$9M$2M
YoY Growth+1.9%-53.6%+38.0%-55.7%-76.2%
Cost of Revenue$1M$2M$2M$2M$78K
Gross Profit$29M$12M$18M$7M$2M
Gross Margin95.3%86.0%91.8%79.9%96.2%
R&D Expenses$28M$32M$37M$29M$10M
SG&A Expenses$14M$14M$16M$14M$10M
Operating Expenses$41M$46M$53M$44M$21M
Operating Income-$13M-$34M-$35M-$37M-$19M
Operating Margin-41.9%-245.2%-181.9%-431.5%-931.2%
Interest Expense$2M$2M$2M$3M$0
Income Before Tax-$14M-$36M-$35M-$28M-$18M
Tax Expense$0$0$0$0$0
Net Income-$13M-$36M-$35M-$28M-$8M
Net Margin-44.6%-259.5%-183.2%-323.2%-409.8%
EPS (Diluted)$-0.67$-1.61$-1.55$-1.20$-0.27
EBITDA-$12M-$34M-$33M-$25M-$19M
Shares Outstanding20M23M23M27M31M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms